Skip to main content

Table 3 Individual components of total pain burden - changes from baseline

From: Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

  Episodic migraine
Overall Monthly Across Months 1 to 6
Chronic migraine
Overall Monthly Across Months 1 to 3
Pain burden individual components, LS mean (SE) Placebo
(n = 872)
Galcanezumab
(n = 435)
LS Mean Difference
(95% CI)
Placebo
(n = 535)
Galcanezumab
(n = 273)
LS Mean Difference
(95% CI)
Number of migraine headache days −2.6 (0.2) −4.5 (0.2)** − 2.0 (− 2.4, − 1.6)** − 2.7 (0.4) −4.8 (0.4)** − 2.1 (− 2.9, − 1.3)**
Hours per migraine headache day 0.1 (0.1) −0.6 (0.1)** − 0.7 (− 0.9, − 0.4)** 0.1 (0.1) −0.5 (0.2)** − 0.7 (− 1.0, − 0.3)**
Severity of remaining migraine headache daysa − 0.2 (0.02) −0.2 (0.02)* − 0.04 (− 0.1–0.0)* − 0.1 (0.02) −0.2 (0.02)** − 0.1 (− 0.1, − 0.03)**
  1. Abbreviations: CI confidence interval, LS least squares, SE standard error
  2. *p < 0.05 versus placebo
  3. **p ≤ 0.001 versus placebo
  4. aSeverity measured as: none = 0, mild = 1, moderate = 2, severe = 3